What is Stellaromics?
Founded in Boston, Stellaromics is at the forefront of biomedical research innovation, developing proprietary technology to map complex three-dimensional transcription and translation patterns in native biological tissue. Its flagship product, STARmap (Spatially-resolved Transcript Amplicon Readout mapping), provides researchers with unprecedented visualization of gene expression within intact tissue. This capability is crucial for identifying novel treatment targets and accelerating the pace of biomedical discovery, positioning Stellaromics as a key player in the life sciences sector.
How much funding has Stellaromics raised?
Stellaromics has raised a total of $105M across 2 funding rounds:
Series A
$25M
Series B
$80M
Series A (2023): $25M with participation from Plaisance Capital Management
Series B (2025): $80M led by Catalyst4 and Stanford University Ventures
Key Investors in Stellaromics
Catalyst4
Catalyst4 is a business and HR consultancy focused on organizational development and strategic planning, likely bringing expertise in scaling operations and market strategy to Stellaromics.
Stanford University Ventures
Stanford University Ventures typically invests in early-stage companies with strong technological foundations, suggesting a focus on Stellaromics' innovative STARmap technology.
Plaisance Capital Management
Plaisance Capital Management is an investment firm that has provided Series A funding, indicating a strategic interest in Stellaromics' growth and market potential.
What's next for Stellaromics?
With the recent major strategic investment, Stellaromics is poised for significant expansion and further technological development. The substantial capital infusion, following its Series B financing, suggests the company is entering a scaling phase, likely focusing on broadening its market reach, enhancing its STARmap technology, and potentially exploring new applications in drug discovery and diagnostics. This strategic backing from investors signals a strong belief in Stellaromics' potential to revolutionize how gene expression is studied, paving the way for breakthroughs in understanding and treating complex diseases.
See full Stellaromics company page
